从实验室研究到临床试验：替莫唑胺在 IDH 突变型胶质瘤中的应用。
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
机构信息
Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.
出版信息
Cells. 2021 May 17;10(5):1225. doi: 10.3390/cells10051225.
Abstract
In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating IDH-mutant glioma. Lastly, we summarize the emerging therapeutic targets that can potentially be used in combination with TMZ.
摘要
在这篇综述中，我们讨论了烷化剂替莫唑胺（TMZ）在 IDH 突变型胶质瘤治疗中的应用。我们描述了 TMZ 在治疗 IDH 突变型胶质瘤的临床（耐药和肿瘤复发）和临床前（体外模型相关的变异性）环境中面临的挑战。最后，我们总结了可能与 TMZ 联合使用的新兴治疗靶点。
Zotero 插件